Enterprise Value
-18.67M
Cash
119.2M
Avg Qtr Burn
-6.453M
Short % of Float
5.16%
Insider Ownership
0.26%
Institutional Own.
62.31%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Fasedienol (PH94B) Details Social Anxiety Disorder | Phase 3 Data readout | |
Itruvone, PH10 (pherine nasal spray ) Details Major depressive disorder | Phase 2b Initiation | |
PH80 ( nasal spray ) Details Menopause, Hot flashes | Phase 2b Initiation | |
Fasedienol (PH94B) (pherine nasal spray) Details Adjustment Disorder | Phase 2a Update | |
AV-101(4-Cl-KYN) (targets the NMDAR) Details Major depressive disorder | Phase 2a Update | |
PH15 (pherine nasal spray) Details Cognitive Dysfunction | Phase 2a Update |